Furiex Pharmaceuticals VP Paul S. Covington Sells 3,228 Shares (FURX)
Furiex Pharmaceuticals (NASDAQ:FURX) VP Paul S. Covington sold 3,228 shares of Furiex Pharmaceuticals stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $104.25, for a total value of $336,519.00. Following the sale, the vice president now directly owns 22,523 shares of the company’s stock, valued at approximately $2,348,023. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of Furiex Pharmaceuticals (NASDAQ:FURX) traded down 0.02% on Tuesday, hitting $104.98. The stock had a trading volume of 49,934 shares. Furiex Pharmaceuticals has a 52-week low of $32.05 and a 52-week high of $121.97. The stock has a 50-day moving average of $104.0 and a 200-day moving average of $79.1. The company’s market cap is $1.134 billion.
Furiex Pharmaceuticals (NASDAQ:FURX) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.62. The company had revenue of $6.40 million for the quarter, compared to the consensus estimate of $10.01 million. During the same quarter in the previous year, the company posted $0.82 earnings per share. The company’s revenue for the quarter was down 83.7% on a year-over-year basis. Analysts expect that Furiex Pharmaceuticals will post $-2.27 EPS for the current fiscal year.
Furiex Pharmaceuticals, Inc is a drug development collaboration company. The Company’s product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.